ClinicalTrials.Veeva

Menu
S

Southwest Family Medicine Associates | Dallas, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Empagliflozin
MK-1242
Vericiguat
Ritonavir
BI 690517
Rocatinlimab
AT-001
Iron
MK-1242-035
Nirmatrelvir

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 24 total trials

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.

Enrolling
Asthma
Drug: Placebo
Drug: Rocatinlimab

The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fract...

Active, not recruiting
Chronic Heart Failure With Reduced Ejection Fraction
Drug: Vericiguat
Drug: Placebo
Locations recently updated

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left...

Enrolling
Heart Failure
Drug: Empagliflozin
Drug: BI 690517

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Obicetrapib
Drug: Placebo

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting
Coronary Heart Disease (CHD)
Drug: Evolocumab
Drug: Placebo

This is a non-blinded, prospective, multi-center, single arm longitudinal cohort study (patient serving as their own control), to evaluate the effect...

Enrolling
Diabetes
Device: Blood glucose meter
Device: Eversense CGM System

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Olpasiran
Drug: Placebo

The purpose of this study is to measure the proportion of participants who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-Co...

Enrolling
SARS-CoV-2 Infection
Drug: Placebo
Drug: S-217622

This is a multicenter, randomized, placebo-controlled, 2-part study to evaluate the safety and efficacy of AT-001 in adult patients (N=675) with Diab...

Active, not recruiting
Diabetic Cardiomyopathies
Drug: AT-001
Drug: Placebo

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

Trial sponsors

Amgen logo
Bayer logo
Akebia Therapeutics logo
American Regent logo
A
Boehringer Ingelheim logo
CSL Behring logo
Duke University logo
G
Janssen (J&J Innovative Medicine) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems